Euprotec is delighted to announce that it is presenting at the SMi’s Superbugs and Superbugs 2012 conference, London, UK, March 5-6^th 2012.  We are proud to be a key sponsor of the event in addition to exhibiting during the two-day conference.

Euprotec’s CEO and CSO will be giving a presentation entitled ‘Multidrug resistant bugs: the pivotal role of preclinical efficacy models in drug discovery’, and will provide a stimulating overview of preclinical models for efficacy determination, emerging resistance and novel approaches to efficacy modelling, and preclinical PK/PD modelling as an aid to design of clinical trials.

Please contact us if you would like to arrange a meeting at this year's conference.

With multidrug resistance ever-increasing on a worldwide scale, advances in antibacterial development have never been more important. This year's conference will consist of a variety of different case study focused presentations featuring real life success stories and failures enabling attendees to learn from and discuss with key industry professionals on challenges facing this rapidly-evolving field.

Now in its 14th Year, SMi's 2012 Superbugs and Superdrugs Conference promises to be a stimulating meeting, bringing together senior industry executives in the field, presenting their experiences of antibiotic resistance and development of new antibacterial agents.

Key areas to be discussed in this year's conference are:

• Therapies to overcome microbial resistance
• Antimicrobial resistant pathogens
• Gram Positive and Gram Negative bacterial infection treatments
• Cell division inhibitors
• Microbiomes as basic defence mechanisms
• Antibody based strategies
• Regulatory requirements for new antimicrobials
• Government incentive schemes